2008 PRESS RELEASE ARCHIVE
August 7, 2008 - GTC Biotherapeutics Completes BLA Submission for AtrynŽ
August 7, 2008 - GTC Biotherapeutics Reports Second Quarter 2008 Financial Results
July 25, 2008 - GTC Biotherapeutics to Transfer to NASDAQ Capital Market
July 18, 2008 - GTC Biotherapeutics Receives NASDAQ Notice of Non-Compliance
July 2, 2008 - GTC Biotherapeutics Receives Notice Related to NASDAQ Minimum Market Value Rule
June 25, 2008 - GTC Biotherapeutics Licenses Recombinant Fibrinogen Patents to Pharming
May 8, 2008 - GTC Biotherapeutics Reports First Quarter 2008 Financial Results
May 8, 2008 - LFB Biotechnologies and GTC Biotherapeutics to Collaborate on rhAAT Program
May 1, 2008 - GTC Biotherapeutics to Host First Quarter 2008 Earnings Call and Webcast on Thursday May 8, 2008March 27, 2008 - GTC Biotherapeutics and Pharmathene Extend Agreement for ProtexiaŽ Program
March 6, 2008 - GTC Biotherapeutics Reports Fourth Quarter and Year End 2007 Financial Results
February 25, 2008 - Last Patient Enrolled in ATrynŽ Pivotal Study
February 8, 2008 - GTC Biotherapeutics to Raise $6 Million in Registered Direct Offering
February 4, 2008 - ATrynŽ Meets Primary Endpoint/Rolling BLA Submission Initiated
January 7, 2008 - ATrynŽ Nears Completion of US HD Clinical Study
Copyright 2008 GTC Biotherapeutics, All Rights Reserved